Navigation Links
Theranostics Health Announces Involvement with Major Academic Medical Center in Study Funded by Susan G. Komen for the Cure(R)

ROCKVILLE, Md., May 26 /PRNewswire/ -- Theranostics Health, Inc. (TH) is pleased to announce its involvement in a five-year clinical research study funded by the Susan G. Komen Foundation. TH's collaborator, Duke University, was the recipient of a Promise Grant, part of over $25 million of investment by the foundation in 2009 to further the development of new prevention and treatment options for breast cancer.

The Susan G. Komen for the Cure(R) is a nonprofit organization dedicated to improving the lives of breast cancer patients through funding groundbreaking research. Since its inception nearly 30 years ago, the foundation has invested over $400 million. This year alone, grants will go to 54 universities and hospitals in 26 states and one foreign country, all for addressing the challenges associated with breast cancer.

Theranostics Health has been collaborating with researchers at Duke University as part of the collaboration agreement established in May 2008. Studies conducted by Theranostics Health with Dr. Victoria Seewaldt, MD, a Duke investigator, have provided the underlying rationale and preliminary data in support of the research proposed for the Promise Grant. Dr. Seewaldt is dedicated to discovering and developing new prevention and treatment strategies for each of her patients afflicted with breast cancer.

Theranostics Health will use its pathway mapping platform to measure signaling pathway activation in hundreds of key signaling proteins directly from randomly obtained periareolar breast fine-needle aspiration to assess individual response to chemoprevention in high-risk patients. This information can be used to develop a rapid test that matches the right prevention agent to each patient based on the biology of abnormal cells in each woman's body.

"The power of this new technology is that it gives us the possibility of tracking how a woman is or is not responding to a prevention drug," said Dr. Victoria Seewaldt. "If this project is successful, it will pave the way for quickly testing the effectiveness of prevention drugs as well as biological response to exercise."

"We are very pleased to have the opportunity of working with first-class research clinicians like Dr. Seewaldt. We share the same vision as Dr. Seewaldt in that each patient's tumor is different and an individualized assessment and approach is needed to effectively prevent and treat diseases," noted Dr. Danong Chen, President and CEO of Theranostics Health.

About Theranostics Health

Theranostics Health (TH) is a privately held company founded in 2006. Its proprietary technology platform includes fixative reagents, Laser Capture Microdissection (LCM), and Reverse Phase Protein Microarray (RPMA). TH's proprietary fixatives are developed to both preserve cell morphology and fix the state of cellular activities for molecular analysis. LCM is used to isolate specific cell populations from many different types of cells usually present in a clinical biopsy. Therefore, information derived from subsequent molecular assays is specific to that cell population. RPMA enables sensitive, quantitative, calibrated, multiplexed analysis of cellular proteins from a limited amount of starting materials, such as clinical specimens. TH has an exclusive license from the National Institute of Health (NIH) to commercialize microdissection, including LCM, combined with protein analysis for cancer diagnostics and companion diagnostics. While providing research and development services to pharmaceutical companies and academic institutions for efficient and effective target discovery and drug development, TH is developing clinical tests, enabling physicians to tailor optimized therapies for patients based on the biomarker profile of each patient's disease specimen. The technology, developed by the company's scientific co-founders, Drs. Emanuel Petricoin and Lance Liotta, was first published in 2001 and in the past 2 years has been used in studies published in more than 50 peer-reviewed journals and presentations. TH's technology was also successfully used in NCI-sponsored clinical trials. For more information please email or visit

SOURCE Theranostics Health
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Three Clinical Studies of bioTheranostics Molecular Breast Cancer Diagnostics Presented at San Antonio Breast Cancer Symposium
2. Theranostics Health Receives Green Light to Perform Clinical Testing
3. American Lung Association Offers Simple Tips to Protect Public Health and Minimize H1N1 Flu (Swine Flu) and Seasonal Flu Transmission
4. New Body of Research Suggests Statin Use Benefits Multiple Areas of Urologic Health
5. Scientists Discover a Role for the Growth Factor TGF-beta in Maintaining Health of Retinal Blood Vessels
6. MedNet Solutions Certified to Score SF-12v2 Health Survey
7. Edifecs, CAQH and Harvard Pilgrim Health Care Will Examine CORE Phase II Testing Outcomes and Lessons Learned at HIMSS09 Interoperability Showcase
8. First Human Study to Show Sun Chlorella A Supports Heart Health
9. Nations Laboratory Response Network Marks First Decade of Protecting Public Health
10. Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data
11. Healthpoint Initiates Phase II, Dose-Finding Study to Evaluate Effectiveness of a Unique Cell Based Therapy in Venous Leg Ulcers
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Amgen (NASDAQ: ... License Application (BLA) with the United States ... ABP 501, a biosimilar candidate to Humira ® ... biosimilar application submitted to the FDA and represents Amgen,s ... Sean E. Harper , M.D., executive vice president ...
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... 25, 2015 On Tuesday, November 24, ... trial against Wright Medical Technology, Inc. for product ... metal-on-metal hip implant device, awarded $11 million in ... week trial and three days of deliberations, the ... was defectively designed and unreasonably dangerous, and that ...
Breaking Medicine Technology:
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... According ... Vinci surgical robot is being more and more widely heralded as a breakthrough for ... da Vinci method has over traditional laparoscopic surgery is that it can greatly reduce ...
(Date:11/25/2015)... Boca Raton, Florida (PRWEB) , ... November 25, ... ... on-site diagnostic testing for physicians and athletic programs, launches new Wimbledon Athletics ... the importance of testing young athletes for unsuspected cardiac abnormalities. About 2,000 people ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... a double board certified facial plastic surgeon specializing in both surgical and non-surgical ... of The Skin Spa at Hobgood Facial Plastic Surgery. , Highly trained ...
(Date:11/25/2015)... , ... November 25, 2015 , ... “While riding the ... inventor, from Bronx, N.Y. “I thought there had to be a convenient and comfortable ... PROTECTOR. , The PROTECTOR enables disabled individuals to safely travel during cold or inclement ...
(Date:11/25/2015)... ... 25, 2015 , ... "When I underwent breast reconstruction following ... uncomfortable," said an inventor from Bronx, N.Y. "In order to meet my own ... BRA for added comfort and support. The bra is easier to put on ...
Breaking Medicine News(10 mins):